Objectives: The emergence of less common, but clinically important, fungal pathogens including the rare yeasts has contributed to the substantial morbidity and mortality observed in immunocompromised patients. These organisms can be resistant or refractory to existing antifungal agents. We sought to evaluate the activity of the new triazole isavuconazole against these difficult pathogens.
Introduction
The emergence of less common, but clinically important, fungal pathogens over the last decade has contributed to the morbidity and mortality observed in the continually expanding immunosuppressed population. 1 Interest has thus increased in the treatment of non-Candida, non-cryptococcal yeasts, including Trichosporon, Geotrichum capitatum (formerly Blastoschizomyces capitatum), Saccharomyces, Pichia and Rhodotorula, as optimal therapy for many of these infections has yet to be defined. In vitro resistance of Trichosporon isolates to the polyenes has been well described, and elevated MICs have also been reported for amphotericin B in Rhodotorula and Geotrichum clinical isolates. 1, 2 The high MIC values reported for the echinocandins and reports of breakthrough infections during prophylactic caspofungin or micafungin therapy suggest that these agents are also unlikely to be effective in the treatment of trichosporonosis or Geotrichum. 1 The triazoles are commonly used during the treatment of these difficult infections as these agents have activity both in vitro and in vivo. However, reduced fluconazole potency has been observed against Trichosporon, Geotrichum and Rhodotorula clinical isolates, 1 -5 Isavuconazole (formerly BAL4815) is a new triazole with broad-spectrum in vitro activity against a number of clinically relevant fungi. 6 However, the activity of this agent against Trichosporon species and the other emerging yeast pathogens has not been reported. We sought to further characterize the in vitro activity of isavuconazole against these uncommon yet clinically significant yeasts, and compare the potency of this azole with that of other clinically available antifungal agents. 
Methods

Isolates
Antifungal agents
MIC and minimum fungicidal concentration (MFC) determination was done in accordance with the CLSI (formerly NCCLS) M27-A2 methodology.
7 Stock solutions were prepared in dimethyl sulphoxide (isavuconazole, voriconazole and amphotericin B), polyethylene glycol ( posaconazole) or water (fluconazole and flucytosine), and were further diluted in RPMI 1640 medium (Sigma, St Louis, MO, USA) buffered with MOPS ( pH 7).
Susceptibility testing
Aliquots of each agent (0.1 mL) at 2Â concentrations were dispensed into 96-well microdilution trays and isolates added to the trays for a starting inoculum of 0.5-2.5Â10 3 cells/mL. Antifungal concentrations ranged from 0.015 to 16 mg/L for isavuconazole, posaconazole, voriconazole and amphotericin B, and from 0.25 to 64 mg/L for fluconazole and flucytosine. The MICs of isavuconazole, posaconazole, voriconazole, fluconazole and flucytosine were read as a 50% reduction in turbidity as compared with growth controls at 72 h. For amphotericin B, MICs were determined as 100% inhibition relative to growth controls. Briefly, MFCs were determined by subculturing 20 mL aliquots from each well that showed complete inhibition after MIC determination (optically clear well) onto Sabouraud dextrose agar. The plates were incubated at 358C and the MFCs read as the lowest drug concentration that resulted in no growth. Candida krusei ATCC 6258 and Candida parapsilosis ATCC 22019 were used as quality controls. ANOVA with Tukey's post-test for multiple comparisons was used to assess differences among the MIC geometric means.
Results
Excellent activity was observed for each of the azoles against the Trichosporon isolates tested. Overall, isavuconazole MIC 50 and MIC 90 values were lower than those of amphotericin B and flucytosine, and lower than or equivalent to the corresponding values of the other azoles tested except voriconazole, whose MIC 50 and MIC 90 values were 1-2 dilutions lower (Table 1) . When compared by geometric means, voriconazole was more potent than the other agents tested against T. asahii (P, 0.05), followed by isavuconazole, which was more potent than posaconazole and fluconazole (P, 0.05). Isavuconazole was also more Table 1 . Similar in vitro susceptibility results were observed against the other rare yeast tested (Table 2 ). Against G. capitatum and Pichia isolates, isavuconazole, voriconazole and posaconazole had similar in vitro potency with MIC 50 and MIC 90 values ranging from 0.03 to 0.5 mg/L. Pichia spp. comprise a heterogeneous genus; however, results across the group were all within two dilutions of one another and no significant species-specific differences were observed. In addition, the geometric MIC values of these agents were significantly less than those of fluconazole (P,0.05) but not those of amphotericin B or flucytosine. Against S. cerevisiae and Rhodotorula species, isavuconazole and voriconazole were the most potent agents tested with MIC 50 and MIC 90 values ranging from 0.03 to 0.25 mg/L. The geometric MIC values of isavuconazole and voriconazole were also significantly lower than those of posaconazole and fluconazole as well as amphotericin B (P, 0.05), but not that of flucytosine. There were no species-specific differences among the Rhodotorula isolates. The activities of isavuconazole, voriconazole and posaconazole were also maintained against the nine Rhodotorula isolates evaluated that were resistant to fluconazole, with MIC values of these extended-spectrum triazoles 0.125 mg/L. Against these yeast species, the MFC values of each azole were higher than those observed for the Trichosporon isolates, with MFC 90 values often exceeding the highest concentration tested.
Discussion
Although rare, infections caused by yeast other than Candida species can be associated with significant morbidity and mortality in immunocompromised patients, including those with haematologic malignancies where the associated mortality rate of infections caused by Trichosporon species and G. capitatum may approach 80%. 8, 9 Although many case reports describe the use of amphotericin B for the treatment of trichosporonosis, in vitro resistance to this polyene has been detected in a number of isolates collected from neutropenic patients with disseminated infection.
1 Furthermore, elevated MICs have also been reported for amphotericin B against Rhodotorula and G. capitatum clinical isolates. 4, 9 The high MIC values reported for the echinocandins plus reports of breakthrough infections in patients receiving caspofungin or micafungin as prophylaxis suggest that these agents are unlikely to be effective in the treatment of these infections. 1 Thus, the optimal treatment for many of these infections has yet to be identified.
One class of agents that is commonly used for these infections is the azoles. Members of this class have demonstrated in vitro and in vivo efficacy against Trichosporon spp. However, high fluconazole MICs have been reported in some isolates. 2 In addition, elevated fluconazole MICs have also been observed against G. capitatum and Rhodotorula clinical isolates. 4, 5 Consistent with the results from other studies, the newer triazoles voriconazole and posaconazole demonstrated potent in vitro activity against T. asahii and non-asahii isolates. 2 In addition, excellent in vitro activity was also observed against the G. capitatum, S. cerevisiae, Pichia and Rhodotorula isolates evaluated.
Isavuconazole is an investigational triazole that may be administered either orally or intravenously as a prodrug that is then converted by plasma esterases into the active component. Previous in vitro studies have demonstrated potent antifungal activity against a number of pathogenic fungal species, including Candida, Aspergillus and Cryptococcus species, and the Zygomycetes. 6, 10 The results of this study demonstrate that isavuconazole also has potent in vitro activity against rare yeast species, including Trichosporon, Saccharomyces, Geotrichum, Pichia and Rhodotorula species, with MIC values similar to those of voriconazole and posaconazole. In addition, these three extended-spectrum triazoles also maintained potent activity against the single T. asahii isolate and numerous Rhodotorula isolates that were resistant to fluconazole. Although it is tempting to speculate that these agents would be effective in the treatment of infections caused by rare yeast resistant to fluconazole, in vivo studies are needed to verify their efficacy in this circumstance.
In summary, emerging rare yeasts have distinct drug susceptibility profiles to which we have sought to characterize the activity of the investigational agent isavuconazole. The in vitro data presented in this study provide encouraging evidence of isavuconazole's activity against these unusual pathogens and further delineate its spectrum of activity. However, clinical data are needed to further define the role of this new agent.
